Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre

Abstract Background Increased homogentisic acid (HGA) causes ochronosis. Nitisinone decreases HGA. The aim was to study the effect of nitisinone on the ochronosis progression. Methods Photographs of the eyes and ears were acquired from patients attending the National Alkaptonuria Centre (NAC) at V‐1...

Full description

Bibliographic Details
Main Authors: Lakshminarayan R. Ranganath, Anna M. Milan, Andrew T. Hughes, Milad Khedr, Andrew S. Davison, Peter J. Wilson, Jane P. Dillon, Elizabeth West, James A. Gallagher
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:JIMD Reports
Subjects:
Online Access:https://doi.org/10.1002/jmd2.12137
id doaj-39244242ead74ac28b7788233f948751
record_format Article
spelling doaj-39244242ead74ac28b7788233f9487512020-11-25T03:41:46ZengWileyJIMD Reports2192-83122020-09-01551758710.1002/jmd2.12137Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria CentreLakshminarayan R. Ranganath0Anna M. Milan1Andrew T. Hughes2Milad Khedr3Andrew S. Davison4Peter J. Wilson5Jane P. Dillon6Elizabeth West7James A. Gallagher8Department of Clinical Biochemistry and Metabolic Medicine Royal Liverpool University Hospital Liverpool UKDepartment of Clinical Biochemistry and Metabolic Medicine Royal Liverpool University Hospital Liverpool UKDepartment of Clinical Biochemistry and Metabolic Medicine Royal Liverpool University Hospital Liverpool UKDepartment of Clinical Biochemistry and Metabolic Medicine Royal Liverpool University Hospital Liverpool UKDepartment of Clinical Biochemistry and Metabolic Medicine Royal Liverpool University Hospital Liverpool UKInstitute of Ageing and Chronic Disease, Musculoskeletal Biology I, William Henry Duncan Building Liverpool UKInstitute of Ageing and Chronic Disease, Musculoskeletal Biology I, William Henry Duncan Building Liverpool UKDepartment of ENT Broadgreen Hospital Liverpool UKInstitute of Ageing and Chronic Disease, Musculoskeletal Biology I, William Henry Duncan Building Liverpool UKAbstract Background Increased homogentisic acid (HGA) causes ochronosis. Nitisinone decreases HGA. The aim was to study the effect of nitisinone on the ochronosis progression. Methods Photographs of the eyes and ears were acquired from patients attending the National Alkaptonuria Centre (NAC) at V‐1 (pre‐baseline visit), V0 (baseline visit when 2 mg nitisinone was commenced), and yearly at V1, V2, and V3 visits. Photographs were inspected for evolution of ochronotic pigment and also scored categorically to derive eye, ear, and combined ochronosis scores. An ear cartilage biopsy was also carried out at V0 and one year after V3 (V4) and ochronotic pigment was assessed and quantitated. Visits were compared for changes in pigment. Fasting blood and 24‐hour urine samples were collected for measurement of HGA. Results There were 80 AKU patients at V0, and 52, 47, and 40 at V1, V2, and V3 in the group with variable numbers (VAR Group) respectively; 23 patients attended once before V0, in the V‐1 visit. Photographs of patients show increase in eye pigment between V‐1 and V0, followed by decrease post‐nitisinone at V1, V2, and V3. Ear and combined ochronosis semiquantitative scoring showed an increase between V‐1 and V0 (P < .01), followed by a decrease at V1, V2, and V3, in the VAR group (P < .01). Ochronotic pigment in ear biopsy between V0 and V4 showed a 19.1% decrease (P < .05). Conclusions Nitisinone decreases HGA and partially reverses ochronosis.https://doi.org/10.1002/jmd2.12137alkaptonurianitisinonehomogentisic acideye ochronosisear ochronosisear cartilage biopsy
collection DOAJ
language English
format Article
sources DOAJ
author Lakshminarayan R. Ranganath
Anna M. Milan
Andrew T. Hughes
Milad Khedr
Andrew S. Davison
Peter J. Wilson
Jane P. Dillon
Elizabeth West
James A. Gallagher
spellingShingle Lakshminarayan R. Ranganath
Anna M. Milan
Andrew T. Hughes
Milad Khedr
Andrew S. Davison
Peter J. Wilson
Jane P. Dillon
Elizabeth West
James A. Gallagher
Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
JIMD Reports
alkaptonuria
nitisinone
homogentisic acid
eye ochronosis
ear ochronosis
ear cartilage biopsy
author_facet Lakshminarayan R. Ranganath
Anna M. Milan
Andrew T. Hughes
Milad Khedr
Andrew S. Davison
Peter J. Wilson
Jane P. Dillon
Elizabeth West
James A. Gallagher
author_sort Lakshminarayan R. Ranganath
title Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
title_short Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
title_full Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
title_fullStr Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
title_full_unstemmed Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
title_sort reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: analysis of data from the united kingdom national alkaptonuria centre
publisher Wiley
series JIMD Reports
issn 2192-8312
publishDate 2020-09-01
description Abstract Background Increased homogentisic acid (HGA) causes ochronosis. Nitisinone decreases HGA. The aim was to study the effect of nitisinone on the ochronosis progression. Methods Photographs of the eyes and ears were acquired from patients attending the National Alkaptonuria Centre (NAC) at V‐1 (pre‐baseline visit), V0 (baseline visit when 2 mg nitisinone was commenced), and yearly at V1, V2, and V3 visits. Photographs were inspected for evolution of ochronotic pigment and also scored categorically to derive eye, ear, and combined ochronosis scores. An ear cartilage biopsy was also carried out at V0 and one year after V3 (V4) and ochronotic pigment was assessed and quantitated. Visits were compared for changes in pigment. Fasting blood and 24‐hour urine samples were collected for measurement of HGA. Results There were 80 AKU patients at V0, and 52, 47, and 40 at V1, V2, and V3 in the group with variable numbers (VAR Group) respectively; 23 patients attended once before V0, in the V‐1 visit. Photographs of patients show increase in eye pigment between V‐1 and V0, followed by decrease post‐nitisinone at V1, V2, and V3. Ear and combined ochronosis semiquantitative scoring showed an increase between V‐1 and V0 (P < .01), followed by a decrease at V1, V2, and V3, in the VAR group (P < .01). Ochronotic pigment in ear biopsy between V0 and V4 showed a 19.1% decrease (P < .05). Conclusions Nitisinone decreases HGA and partially reverses ochronosis.
topic alkaptonuria
nitisinone
homogentisic acid
eye ochronosis
ear ochronosis
ear cartilage biopsy
url https://doi.org/10.1002/jmd2.12137
work_keys_str_mv AT lakshminarayanrranganath reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT annammilan reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT andrewthughes reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT miladkhedr reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT andrewsdavison reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT peterjwilson reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT janepdillon reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT elizabethwest reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
AT jamesagallagher reversalofochronoticpigmentationinalkaptonuriafollowingnitisinonetherapyanalysisofdatafromtheunitedkingdomnationalalkaptonuriacentre
_version_ 1724528414194401280